Profound Medical (PROF) Net Equity Issued and Repurchased (2024)
Profound Medical's (PROF) quarterly Net Equity Issued and Repurchased came in at $39.2 million in Q4 2024, up 70.76% quarter-over-quarter from $22.9 million in Q1 2024.
Profound Medical (PROF) Net Equity Issued and Repurchased (2024) Analysis & Trends
Profound Medical's Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $39.2 million for Q4 2024.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $39.2 million in Q4 2024; TTM through Dec 2024 was $62.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $42.4 million, down 31.67% from the prior year.
- Net Equity Issued and Repurchased advanced to $39.2 million in Q4 2024 per PROF's latest filing, from $22.9 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $39.2 million in Q4 2024 and bottomed at $22.9 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 97.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 12.70 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Profound Medical | 248.64 Mn | 198.34 Mn | 3.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 39.17 Mn |
| Dec 31, 2024 | 39.17 Mn |
| Mar 31, 2024 | 22.94 Mn |
| Mar 31, 2024 | 22.94 Mn |